<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676310</url>
  </required_header>
  <id_info>
    <org_study_id>192024-085</org_study_id>
    <nct_id>NCT02676310</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)</brief_title>
  <official_title>Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients
      with androgenetic alopecia (AGA).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>42 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale</measure>
    <time_frame>Baseline, 42 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma level (Cmax) of bimatoprost and its acid metabolite</measure>
    <time_frame>31 Days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Alopecia</condition>
  <condition>Alopecia, Androgenetic</condition>
  <condition>Baldness</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Bimatoprost 0.3% (Formulation B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Bimatoprost 1% (Formulation A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Bimatoprost 1% (Formulation B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Bimatoprost 1% (Formulation B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Bimatoprost 3% (Formulation B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost</intervention_name>
    <arm_group_label>Cohort 1: Bimatoprost 0.3% (Formulation B)</arm_group_label>
    <arm_group_label>Cohort 2: Bimatoprost 1% (Formulation A)</arm_group_label>
    <arm_group_label>Cohort 2: Bimatoprost 1% (Formulation B)</arm_group_label>
    <arm_group_label>Cohort 3: Bimatoprost 1% (Formulation B)</arm_group_label>
    <arm_group_label>Cohort 4: Bimatoprost 3% (Formulation B)</arm_group_label>
    <other_name>Bimatoprost Solution applied onto pre-specified area on the scalp daily for 28 days.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss
             for at least 1 year

        Exclusion Criteria:

          -  History of Paget's disease, osteoporosis, or bone malignancy

          -  History of bone fracture within the previous 12 months, except for metatarsal,
             metacarpal, or skull fractures

          -  Patient is currently undergoing radiation therapy or anticipates undergoing radiation
             therapy at any time during the study

          -  Drug or alcohol abuse within 12 months

          -  HIV positive

          -  Received hair transplants or had scalp reductions

          -  Use of hair weaves, hair extensions or wigs within 3 months

          -  Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs
             (NSAIDs) to scalp within 4 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E&amp;R Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

